Uridine diphosphate derivatives, prodrugs, compositions and uses thereof

Abstract

This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

What is claimed is: 
     
         1 . A method for treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of
 a compound of formula I:   
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein: 
       A is a 3- to 10-membered aromatic or non-aromatic ring having up to 5 heteroatoms independently selected from N, O, S, SO, or SO 2 , wherein the aromatic or non-aromatic ring is independently and optionally substituted with one or more R 7 ; 
       X is independently selected from O, S, N(R 5 )— and a (C1-C3)-aliphatic group independently and optionally substituted with one or more R 4 ; 
       Y is a bond or a (C1-C5)-aliphatic group independently and optionally substituted with one or more R 4 ; 
       Z and W are each independently selected from ═O, ═S, ═N(R 5 ), and ═NOR 5 ; 
       R 1  is selected from:
 —H, halogen, —OR 5 , —CN, —CF 3 , —OCF 3  and a (C1-C6)-aliphatic group optionally substituted with one or more R 7 ; 
 
       R 2  and R 3  are each independently selected from —OR 5 , —SR 5 , —NR 5 R 6 , —OC(O)R 5 , —OC(O)NR 5 R 6 , and —OC(O)OR 5 ; 
       each occurrence of R 4  is independently selected from:
 halogen, —OR 5 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 5 , 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 5 ) 2 , —SR 5 , —SOR 5 , —SO 2 R 5 , —SO 2 N(R 5 ) 2 , —SO 3 R 5 , —C(O)R 5 , —C(O)C(O)R 5 , —C(O)CH 2 C(O)R 5 , —C(S)R 5 , —C(S)OR 5 , —C(O)OR 5 , —C(O)C(O)OR 5 , —C(O)C(O)N(R 5 ) 2 , —OC(O)R 5 , —C(O)N(R 5 ) 2 , —OC(O)N(R 5 ) 2 , —C(S)N(R 5 ) 2 , —(CH 2 ) 0-2 NHC(O)R 5 , —N(R 5 )N(R 5 )COR 5 , —N(R 5 )N(R 5 )C(O)OR 5 ,— N(R 5 )N(R 5 )CON(R 5 ) 2 , 
 —N(R 5 )SO 2 R 5 , —N(R 5 )SO 2 N(R 5 ) 2 , —N(R 5 )C(O)OR 5 , —N(R 5 )C(O)R 5 , —N(R 5 )C(S)R 5 , —N(R 5 )C(O)N(R 5 ) 2 , —N(R 5 )C(S)N(R 5 ) 2 , —N(COR 5 )COR 5 , —N(OR 5 )R 5 , —C(═NH)N(R 5 ) 2 , —C(O)N(OR 5 )R 5 , —C(═NOR 5 )R 5 , —OP(O)(OR 5 ) 2 , —P(O)(R 5 ) 2 , —P(O)(OR 5 ) 2 , or —P(O)(H)(OR 5 ); 
 
       each occurrence of R 5  is independently selected from:
 H—, 
 (C1-C12)-aliphatic-, 
 (C3-C10)-cycloalkyl- or -cycloalkenyl-, 
 [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-, 
 (C6-C10)-aryl-, 
 (C6-C10)-aryl-(C1-C12)aliphatic-, 
 (C3-C10)-heterocyclyl-, 
 (C6-C10)-heterocyclyl-(C1-C12)aliphatic-, 
 (C5-C10)-heteroaryl-, and 
 (C5-C10)-heteroaryl-(C1-C12)-aliphatic-; 
 wherein two R 5  groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, O, S, SO, or SO 2 , wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl; and 
 wherein each R 5  group is independently and optionally substituted with one or more R 7 ; 
 
       R 6  is selected from:
 —R 5 , —C(O)R 5 , —C(O)OR 5 , —C(O)N(R 5 ) 2  and —S(O) 2 R 5 ; 
 
       each occurrence of R 7  is independently selected from:
 halogen, —OR 8 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 8 , oxo, thioxo, 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 8 ) 2 , —SR 8 , —SOR 8 , —SO 2 R 8 , —SO 2 N(R 8 ) 2 , —SO 3 R 8 , —C(O)R 8 , —C(O)C(O)R 8 , —C(O)CH 2 C(O)R 8 , —C(S)R 8 , —C(S)OR 8 , —C(O)OR 8 , —C(O)C(O)OR 8 , —C(O)C(O)N(R 8 ) 2 , —OC(O)R 8 , —C(O)N(R 8 ) 2 , —OC(O)N(R 8 ) 2 , —C(S)N(R 8 ) 2 , —(CH 2 ) 0-2 NHC(O)R 8 , —N(R 8 )N(R 8 )COR 8 , —N(R 8 )N(R 8 )C(O)OR 8 , —N(R 8 )N(R 8 )CON(R 8 ) 2 , 
 —N(R 8 )SO 2 R 8 , —N(R 8 )SO 2 N(R 8 ) 2 , —N(R 8 )C(O)OR 8 , —N(R 8 )C(O)R 8 , —N(R 8 )C(S)R 8 , —N(R 8 )C(O)N(R 8 ) 2 , —N(R 8 )C(S)N(R 8 ) 2 , —N(COR 8 )COR 8 , —N(OR 8 )R 8 , —C(═NH)N(R 8 ) 2 , —C(O)N(OR 8 )R 8 , —C(═NOR 8 )R 8 , —OP(O)(OR 8 ) 2 , —P(O)(R 8 ) 2 , —P(O)(OR 8 ) 2 , or —P(O)(H)(OR 8 ); and 
 
       each occurrence of R 8  is independently selected from:
 H— and (C1-C6)—aliphatic. 
 
     
     
         2 . The method of  claim 1 , wherein the inflammatory condition is an inflammatory condition of the eye. 
     
     
         3 . The method of  claim 2 , wherein the inflammatory condition is selected from the group consisting of uveitis, conjunctivitis, scleritis, and keratoconjunctivitis sicca. 
     
     
         4 . The method of  claim 2 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.